

DAFTAR PUSTAKA

Abu Samaan, T.M., Samec, M. Liskova, A., Kubatka, P., Busselberg, D. (2019).

Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer. *Biomolecules*,

9(12).

Retrieved

from

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995578/>

Alkabban, F.M., Ferguson, T. (2022). *Breast Cancer*. Treasure Island (FL): StatPearls

Publishing, <https://www.ncbi.nlm.nih.gov/books/NBK482286/>.

Amjad, M.T., Chidaharla A., Kasi, A. (2024). *Cncer Chemotherapy*. Retrieved from

In: StatPearls: <https://www.ncbi.nlm.nih.gov/books/NBK564367/>

Anggorowati, L. (2013). Faktor Risiko Kanker Payudara Wanita. *Jurnal Kesehatan*

Masyarakat, 8(2), 121-126.

Ashariati, A. (2019). *Manajemen Kanker Payudara Komprehensif*. Surabaya:

Universitas Airlangga Press.

Bujanda, D.A., Sarmiento, U.B., Suarez, M.A.C., Ruiz, M.P., Gonzalez, M.A.L.,

Morales, J.A. (2006). Epirubicin, Cyclophosphamide and Paclitaxel as

Neoadjuvant Chemotherapy for Stage II and III Breast Cancer. *Journal of*

Cancer Research and Clinical Oncology, 132, 332-338.

Cameron, D.A., Gabra, H., Leonard, R.C.F. (1994). Continuous 5-Fluorouracil in the

Treatment of Breast Cancer. *J. Cancer*, 70, 120-124.

- Fan, C., Georgioun K.R., McKinnon, R.A. et al. (2016). Combination Chemotherapy with Cyclophosphamide, Epirubicin, and 5-Fluorouracil Causes Trabecular Bone Loss, Bone Marrow Cell Depletion and Marrow Adiposity in Female Rats. *J Bone Miner Metab* 34, 277-290.
- Feng, Y., dkk. (2018). Breast Cancer Development and Progression: Risk Factors, Cancer Stem Cells, Signaling Pathways, Genomics, and Molecular Pathogenesis. *Genes & Disease* 5, 77-106.
- Gautama, W. (2022). Breast Cancer in Indonesia in 2022: 30 Years of Marching Place. *Indonesian Journal of Cancer*, 16 (1).
- Haryani, S. (2022). Evaluasi Penggunaan Obat Kemoterapi Pada Pasien Kanker Payudara di RSUP Fatmawati Periode Februari 2021. *Jurnal Farmasi Klinik - Base Practice*, 1(1), 50-60.
- Hidayat, Y. M. (2013). Prinsip Dasar Kemoterapi. In *Bandung Controversies and Consensus in Obstetrics & Gynecology* (pp. 253-273). Jakarta: Sagung Seto.
- Hidayati, T., Akrom. (2021). *Epidemiologi & Biomolekuler Kanker*. Jakarta: Azkiya Publisher.
- Irawati, Sardjan, M. (2022). Pola Peresepan Obat Kemoterapi Kanker Payudara di Rumah Sakit Lavalette Kota Malang. *Jurnal Kefarmasian dan Gizi*, 1(2), 80-85.

Kementerian Kesehatan RI. (2013). *Pedoman Teknis Pengendalian Kanker Payudara & Kanker Leher Rahim*. Jakarta: Direktorat Pengendalian Penyakit Tidak Menular.

Khasraw, M., Bell, R., Dang, C. (2012). Epirubicin: Is it Like Doxorubicin in Breast Cancer? A Clinical Review. *The Breast*, 21, 142-149.

Khattab, A., Kashyap, S., Monga, D.K. (2022). *Male Breast Cancer*. Retrieved from In: StatPearls Publishing: <https://www.ncbi.nlm.nih.gov/books/NBK526036/>

KPKN. (2015). *Panduan Nasional Penanganan Kanker Payudara*. Jakarta: Kementerian Kesehatan Republik Indonesia.

KPKN. (2017). *Panduan Penatalaksanaan Kanker Payudara*. Jakarta: Kementerian Kesehatan Republik Indonesia.

Liambo, I.S., Fristiohady, A., Malaka, M.H. (2022). Review: Patofisiologi, Epidemiologi, dan Lini Sel Kanker Payudara. *Pharmaujo: Jurnal Farmasi, Sains, dan Kesehatan*, 8(1), 17-22.

Lyon, F.R. (2012). Cyclophosphamide. *Pharmaceuticals*.

Lyseng-Williamson, K.A., Fenton, C. (2005). Docetaxel: A Review of its Use in Metastatic Breast Cancer. *Drugs* 65, 2513-2531.

Marsanti, Febriana, C.A., Ibrahim, A., Rahmawati, D. (2016). *Karakteristik dan Pola*

Pengobatan Pasien Kanker Payudara di RSUD Abdul Wahab Sjahranie.

Fakultas Farmasi, Universitas Mulawarman.

Na, Z., et.al. (2017). A Developed Model of Cancer Patients Participation in

Intravenous Chemotherapy Safety. *Oncotarget*, 8(50), 87598-87606.

NIH. (2022). *Chemotherapy to Treat Cancer*. [https://www.cancer.gov/about-](https://www.cancer.gov/about-cancer/treatment/types/chemotherapy)

[cancer/treatment/types/chemotherapy](https://www.cancer.gov/about-cancer/treatment/types/chemotherapy).

Saptowulan, S., Maulina, D. (2023). Gambaran Peresepan Kemoterapi Oral Pada

Pasien Kanker Payudara di RS X di Jakarta Timur. *Indonesian Journal of*

Health Science, 3(2), 136-142.

Shafei, A., et. al. (2017, 95). A Review on the Efficacy and Toxicity of Different

Doxorubicin Nanoparticles for Targeted Therapy in Metastatic Breast Cancer.

Biomedicine & Pharmacotherapy, 1209-1218.

Sulistiyawati, W. W. (2022). Analisis (Deskriptif Kuantitatif) Motivasi Belajar Siswa

Dengan Model Blended Learning di Masa Pandemi COVID19. *Kadikma*,

13(1), 68-73.

Tredeau, M.E., et. al. (1996). Docetaxel in Patients with Metastatic Breast Cancer: A

Phase II Study of the National Cancer Institute of Canada - Clinical Trials

Group. *J. Clin Oncol*, 14(2), 422-428.

Zenab, S. (2013). Studi Pola Penggunaan Obat Kemoterapi Pada Pasien Carcinoma
Mammae Tahun 2011-2012 di Rumah Sakit Prof. Dr. H. Aloei Saboe Kota
Gorontalo. Fakultas Ilmu-Ilmu Kedokteran dan Keolahragaan, Universitas
Negeri Gorontalo.